Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib

被引：16
|
作者：
Zhu, You-Cai [1 ]
Wang, Wen-Xian [2 ]
Xu, Chun-Wei [3 ]
Tan, Qing-He [4 ]
Li, Jian-Ying [4 ]
Zhuang, Wu [5 ]
Song, Zheng-Bo [2 ]
Du, Kai-Qi [1 ]
Chen, Gang [3 ]
Lv, Tang-Feng [6 ]
Song, Yong [6 ]
机构：
[1] Zhejiang Rongjun Hosp, Dept Thorac Dis Diag & Treatment Ctr, Jiaxing 314000, Peoples R China
[2] Zhejiang Canc Hosp, Dept Chemotherapy, 1 Banshan East St, Hangzhou 310022, Zhejiang, Peoples R China
[3] Fujian Med Univ, Canc Hosp, Fujian Canc Hosp, Dept Pathol, Fuzhou 350014, Fujian, Peoples R China
[4] Nantong Tumor Hosp, Dept Oncol, Nantong 226361, Peoples R China
[5] Fujian Med Univ, Canc Hosp, Fujian Canc Hosp, Dept Med Thorac Oncol, Fuzhou 350014, Fujian, Peoples R China
[6] Jinling Hosp, Dept Resp Med, Nanjing 210002, Jiangsu, Peoples R China
来源：
JOURNAL OF THORACIC DISEASE | 2018年 / 10卷 / 05期
关键词：
CANCER; MUTATIONS; GEFITINIB; CHEMOTHERAPY;
D O I：
10.21037/jtd.2018.04.162
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：E359 / E363
页数：5
相关论文
共 50 条
  • [41] EGFR polymorphism of the kinase domain in Japanese lung cancer
    Sasaki, Hidefumi
    Endo, Katsuhiko
    Takada, Minoru
    Kawahara, Masaaki
    Tanaka, Hisaichi
    Kitahara, Naoto
    Matsumura, Akihide
    Iuchi, Keiji
    Kawaguchi, Tomoya
    Okuda, Katsuhiro
    Kawano, Osamu
    Yukiue, Harubiro
    Yokoyama, Tomoki
    Yano, Motoki
    Fujii, Yoshitaka
    [J]. JOURNAL OF SURGICAL RESEARCH, 2008, 148 (02) : 260 - 263
  • [42] Marked Response to Icotinib in Lung Squamous Cell Carcinoma with EGFR Wild-Type
    Fan, Tao
    Zhou, Ju-Ying
    [J]. JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2018, 28 (06): : S120 - S122
  • [43] The landscape of kinase domain duplication in Chinese lung cancer patients
    Wu, Di
    Xie, Yuancai
    Jin, Chang'e
    Qiu, Jinfan
    Hou, Ting
    Du, Haiwei
    Chen, Songan
    Xiang, Jianxing
    Shi, Xi
    Liu, Junling
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (24)
  • [44] Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma
    Watanabe, Satoshi
    Sone, Takashi
    Matsui, Tomoharu
    Yamamura, Kenta
    Tani, Mayuko
    Okazaki, Akihito
    Kurokawa, Koji
    Tambo, Yuichi
    Takato, Hazuki
    Ohkura, Noriyuki
    Waseda, Yuko
    Katayama, Nobuyuki
    Kasahara, Kazuo
    [J]. LUNG CANCER, 2013, 82 (02) : 370 - 372
  • [45] Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient
    Hu, Yijuan
    Xiao, Lili
    Yang, Nong
    Zhang, Yongchang
    [J]. THORACIC CANCER, 2019, 10 (05) : 1252 - 1255
  • [46] Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
    Nicos, Marcin
    Wojas-Krawczyk, Kamila
    Krawczyk, Pawel
    Chmielewska, Izabela
    Wojcik-Superczynska, Magdalena
    Reszka, Katarzyna
    Kieszko, Robert
    Gora-Florek, Anna
    Dudek, Malgorzata
    Swiniuch, Daria
    Papiewski, Wojciech
    Calka, Paulina
    Ciesielka, Marzanna
    Ramlau, Rodryg
    Milanowski, Janusz
    [J]. ARCHIVES OF MEDICAL SCIENCE, 2020, 16 (06) : 1496 - 1500
  • [47] Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma
    Tatsuya Yoshida
    Genichiro Ishii
    Koichi Goto
    Kiyotaka Yoh
    Seiji Niho
    Shigeki Umemura
    Shingo Matsumoto
    Hironobu Ohmatsu
    Kanji Nagai
    Yuichiro Ohe
    Atsushi Ochiai
    [J]. Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1691 - 1700
  • [48] Extraordinary Response to Erlotinib Therapy in a Patient with Lung Adenocarcinoma Exhibiting KRAS Mutation and EGFR Amplification
    Krejci, J.
    Pesek, M.
    Grossmann, P.
    Krejci, M.
    Ricar, J.
    Benesova, L.
    Minarik, M.
    [J]. CANCER GENOMICS & PROTEOMICS, 2011, 8 (03) : 135 - 138
  • [49] Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma
    Yoshida, Tatsuya
    Ishii, Genichiro
    Goto, Koichi
    Yoh, Kiyotaka
    Niho, Seiji
    Umemura, Shigeki
    Matsumoto, Shingo
    Ohmatsu, Hironobu
    Nagai, Kanji
    Ohe, Yuichiro
    Ochiai, Atsushi
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (10) : 1691 - 1700
  • [50] Patient With Stage IV NSCLC and CNS Metastasis With EGFR Exon 18-25 Kinase Domain Duplication With Response to Osimertinib as a First-Line Therapy
    Kim, Jong Taek
    Zhang, Wenjuan
    Lopategui, Jean
    Vail, Eric
    Balmanoukian, Ani
    [J]. JCO PRECISION ONCOLOGY, 2021, 5 : 88 - 92
12345